Introduction of a Quadrivalent Influenza Vaccine in Italy: A Budget Impact Analysis

Journal of Preventive Medicine and Hygiene

Volumn 57, Issue 1, 2016, Pages E34-E40

  Pitrelli, A ^a  

^a GSK   (Italy)

Author keywords

Budget Impact Analysis; Influenza; QIV

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; BUDGET; CHILD; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SURVEILLANCE; DRUG EFFECT; HUMAN; INFECTION PREVENTION; INFLUENZA A; INFLUENZA A VIRUS; INFLUENZA B; INFLUENZA B VIRUS; INFLUENZA VACCINATION; ITALY; MAJOR CLINICAL STUDY; MIDDLE AGED; NONHUMAN; POPULATION RESEARCH; PRESCHOOL CHILD; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCHOOL CHILD; VERY ELDERLY; VIRUS STRAIN; YOUNG ADULT;

EID: 84979201242     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012;8:81-8.
2. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, Sebastian R, Chong M, Tam T, De Serres G. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007;25:2842-51.
3. Beran J, Wertzova V, Honegr K, Kaliskova E, Havlickova M, Havlik J, Jirincova H, Van Belle P, Jain V, Innis B, Devaster JM. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009;9:2.
4. Skowronski DM, De SG, Dickinson J, Petric M, Mak A, Fonseca K, Kwindt TL, Chan T, Bastien N, Charest H, Li Y. Component- specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 2009;199:168-79.
5. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culturederived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010;51:997-1004.
6. Belongia EA, Kieke BA, Donahue JG, Coleman LA, Irving SA, Meece JK, Vandermause M, Lindstrom S, Gargiullo P, Shay DK. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine 2011;29:6558-63.
7. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpaa R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011;11:23-9.
8. Janjua NZ, Skowronski DM, De SG, Dickinson J, Crowcroft NS, Taylor M, Winter AL, Hottes TS, Fonseca K, Charest H, Drews SJ, Sabaiduc S, Bastien N, Li Y, Gardy JL, Petric M. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants. J Infect Dis 2012;205:1858-68.
9. Gazzetta Ufficiale Numero Determina 364/2015. Available at: www.gazzettaufficiale.it [Accessed 05/01/16].
10. Prevenzione e controllo dell'influenza: raccomandazioni per la stagione 2015-2016. Ministero della Salute Direzione Generale Della Prevenzione Sanitaria - CCM Ufficio V ex DGPREV - Malattie Infettive e Profilassi Internazionale. Available at: http://www.salute.gov.it/portale/news/p3-2-1-1-1.jsp?menu=notizie&p=dalministero&id=2218. [Accessed 05/01/16].
11. Barbieri M, Silvestri R, Boccalini S, de Waure C. Analisi di costo- efficacia della vaccinazione anti-influenzale in Italia. QIJPH 2015;5:70-83.
12. National Demographic Institute. ISTAT. Available at: http://demo.istat.it [Accessed 05/01/16].
13. Ryan J, Zoellner Y, Gradi B, Palache B, Medema J. Establishing the health economic impact of influenza vaccination within European Union 25 Countries. Vaccine 2006;24:6812-22.
14. Vaccinazione antinfluenzale: stagione 2013/2014. Elaborazione MinSal - ISS aggiornamento 10/06/14. Available at: www.salute. gov [Accessed 05/01/16].
15. Rapporto Nazionale Passi 2012: vaccinazione antinfluenzale stagionale http://www.epicentro.iss.it/passi/rapporto2012/vaccinazioneAntinluenzale.asp
16. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modeling for the prevention and treatment of influenza A and B. Health Technol Assess 2003;7:iii-iv, xi-xiii, 1-170.
17. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008;2:CD004879.
18. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010;7:CD001269.
19. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2014;3:CD001269.
20. Tricco AC. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and metaanalysis. BMC Med 2013;11:153.
21. Sessa A, Costa B, Bamfi F, Bettoncelli G, D'Ambrosio G. The incidence, natural history and associated outcomes of influenza like illness and clinical influenza in Italy. Family Practice 2001;18:629-34.
22. Esposito S, Cantarutti L, Molteni CG, Daleno C, Scala A, Tagliabue C, Pelucchi C, Giaquinto C, Principi N. Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J Infection 2011;62:379-87.
23. Iannazzo S. Pharmacoeconomic evaluation of the MF59 adjuvanted influenza vaccine in the elderly population in Italy. J Prev Med Hyg 2011;52:1-8.
24. Unit cost: IMS data, Dosing, from the electronic Medicines Compendium (eMC) 2014: Zanamivir. Available at: http://www.medicines.org.uk/emc/medicine/2608 [Accessed 05/01/16].
25. Unit cost: IMS data, Dosing, from the electronic Medicines Compendium (eMC) 2014: Oseltamivir. Available at https://www.medicines.org.uk/emc/medicine/10446/SPC/Tamiflu+75mg+hard+capsule/[Accessed 05/01/16].
26. Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, Nicholson K. Amantadine, oseltamvir and zanamavirfor the prophylaxis of influenza A systematic review and economic evaluation. HTA 2009;11:73-5.